Lake Street Capital Cuts OptiNose (NASDAQ:OPTN) Price Target to $17.00

OptiNose (NASDAQ:OPTN) had its price target reduced by Lake Street Capital from $45.00 to $17.00 in a report published on Thursday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright lifted their price target on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Piper Sandler reduced their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th.

OptiNose Trading Up 5.8 %

Shares of OPTN opened at $6.38 on Thursday. OptiNose has a twelve month low of $4.82 and a twelve month high of $31.50. The firm has a market capitalization of $64.18 million, a P/E ratio of -1.52 and a beta of -0.15. The stock’s fifty day simple moving average is $6.79 and its 200 day simple moving average is $11.10.

Institutional Trading of OptiNose

Large investors have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its stake in shares of OptiNose by 442.3% during the second quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock valued at $14,425,000 after acquiring an additional 10,944,444 shares in the last quarter. Great Point Partners LLC grew its stake in OptiNose by 56.2% during the 2nd quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after purchasing an additional 4,940,779 shares in the last quarter. Stonepine Capital Management LLC increased its holdings in OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock worth $3,811,000 after purchasing an additional 3,338,580 shares during the last quarter. Rosalind Advisors Inc. increased its stake in shares of OptiNose by 9.8% in the third quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company’s stock worth $5,553,000 after buying an additional 740,355 shares during the last quarter. Finally, FMR LLC boosted its stake in OptiNose by 3.2% during the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock valued at $11,083,000 after acquiring an additional 518,610 shares during the last quarter. Institutional investors and hedge funds own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.